Standout Papers

Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A... 2001 2026 2009 2017 1.3k
  1. Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B (2002)
    Lewis R. Silverman, Erin P. Demakos et al. Journal of Clinical Oncology
  2. Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion (2006)
    Alan F. List, Gordon W. Dewald et al. New England Journal of Medicine
  3. United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia (2001)
    Steven L. Soignet, Stanley R. Frankel et al. Journal of Clinical Oncology
  4. Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission (2009)
    John Koreth, Richard F. Schlenk et al. JAMA
  5. Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity (2019)
    Peter van Galen, Volker Hovestadt et al. Cell
  6. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations (2014)
    R. Coleman Lindsley, Brenton G. Mar et al. Blood
  7. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 (2004)
    Richard M. Stone, Daniel J. DeAngelo et al. Blood
  8. Report of an international working group to standardize response criteria for myelodysplastic syndromes. (2000)
    Bruce D. Cheson, John M. Bennett et al. PubMed
  9. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients (2014)
    Rafael Bejar, Allegra M. Lord et al. Blood
  10. Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management (2023)
    Shai Shimony, Maximilian Stahl et al. American Journal of Hematology
  11. Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis (2023)
    Lachelle D. Weeks, Abhishek Niroula et al. NEJM Evidence
  12. Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management (2025)
    Shai Shimony, Maximilian Stahl et al. American Journal of Hematology

Immediate Impact

15 by Nobel laureates 14 from Science/Nature 73 standout
Sub-graph 1 of 19

Citing Papers

Acute myeloid leukaemia
2023 Standout
A neutrophil response linked to tumor control in immunotherapy
2023 Standout

Works of Richard M. Stone being referenced

FcγR engagement reprograms neutrophils into antigen cross-presenting cells that elicit acquired anti-tumor immunity
2021
Safety and Efficacy of Menin Inhibition in Patients (Pts) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: A Phase (Ph) 1, First-in-Human Study of SNDX-5613 (AUGMENT 101)
2021
and 1 more

Author Peers

Author Last Decade Papers Cites
Richard M. Stone 16957 10725 6596 730 26.5k
Pierre Fenaux 27316 15453 11127 861 36.1k
Martin S. Tallman 22806 14572 6880 707 34.0k
Farhad Ravandi 24108 12709 10098 1.3k 33.6k
Mark R. Litzow 11567 5368 4734 585 18.3k
Elihu H. Estey 27135 15777 8556 679 39.0k
Michael J. Borowitz 12420 4733 5825 324 22.4k
Gareth J. Morgan 16766 14621 4238 838 29.7k
Deborah A. Thomas 12009 6207 10024 448 22.7k
John M. Bennett 28276 11357 10923 386 40.2k
Jerald P. Radich 16407 4888 9835 393 21.5k

All Works

Loading papers...

Rankless by CCL
2026